Tamsulosin Treatment for Benign Prostatic Hyperplasia

Primary Indication and Mechanism

The standard dosage of tamsulosin is 0.4 mg once daily in a modified-release formulation, with no need for initial dose titration, as recommended by urological guidelines 1

Tamsulosin is associated with intraoperative floppy iris syndrome during cataract surgery, which should be considered in patients planning ophthalmic procedures, according to the European Urology guidelines 2
The American Urological Association notes that alpha blockers like tamsulosin do not affect prostate size, and therefore should not be used to reduce prostate volume [@29@, 2]
Patients undergoing cataract surgery should be informed about their tamsulosin use, as it can complicate the procedure, as advised by the European Urology guidelines [@33@, 2]
The Journal of Urology reports that tamsulosin has a higher risk of ejaculatory dysfunction compared to other alpha blockers 1

The European Association of Urology recommends that tamsulosin be considered for patients with benign prostatic hyperplasia and acute urinary retention, as it facilitates successful voiding after catheter removal, with a standard dosing of 0.4 mg once daily 3, 4, 5

For patients with significantly enlarged prostates, the European Urology guidelines suggest combination therapy with a 5-alpha-reductase inhibitor, such as finasteride or dutasteride, for long-term management 3, 4, 5

The standard patient for tamsulosin treatment is a man older than 50 years presenting with bothersome moderate-to-severe lower urinary tract symptoms (LUTS) that may or may not be associated with an enlarged prostate, according to the American Urological Association guidelines 6
Tamsulosin is appropriate for men with voiding symptoms (hesitancy, weak stream, incomplete emptying, intermittency) rather than predominantly storage symptoms (urgency, frequency) 6